Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: A case-controlled, multicenter study

Mohammad Alyami 1 Peter Lundberg 1 Vahan Kepenekian 1 Diane Goere 2 Jean-Marc Bereder 3 Simon Msika 4 Gérard Lorimier 5 François Quenet 6, 7 Gwenaël Ferron 8 Emilie Thibaudeau 9 Karine Abboud 10 Réa Lo Dico 11 Delphine Delroeux 12 Cécile Brigand 13 Catherine Arvieux 14 Frédéric Marchal 15, 16 Jean-Jacques Tuech 17 Jean-Marc Guilloit 18 Frédéric Guyon 19 Patrice Peyrat 20 Denis Pezet 21 Pablo Ortega-Deballon 22 Franck Zinzindohoué 23 Cécile de Chaisemartin 24 Reza Kianmanesh 25 Olivier Glehen 1, 26 Guillaume Passot 1, 26 Big-Renape Group Renape Group
Abstract : OBJECTIVE: This study was designed to identify factors associated with morbidity and mortality in patients older than 70 years who underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC). BACKGROUND: Major surgery is associated with higher morbidity and mortality in elderly patients. For PC, CRS and HIPEC is the only current potential curative therapy, but the risks inherent to this patient population have called its benefits into question. METHODS: We retrospectively analyzed a multi-center database from 1989 to 2015. All patients who underwent CRS and HIPEC for PC were selected and patients older than 70 years were matched 1:4 with a younger cohort according to cancer origin, peritoneal cancer index (PCI), and completeness of cytoreduction. Major morbidity and mortality were analyzed. RESULTS: Of 2328 patients, 188 patients older than aged 70 years were matched with 704 younger patients. Patients older than aged 70 years demonstrated a higher American Society of Anesthesiologist score (≥ASA III 10.8 vs. 6.6 %, p = 0.008). There was no difference in overall 90-day morbidity (≥70: 45.7 % vs. <70: 44.5 %; p = 0.171); however, patients older than 70 years had significantly more cardiovascular complications (13.8 vs. 9.2 %, p = 0.044). Differences between the older and younger cohorts failed to reach significance for 90-day mortality (5.4 and 2.7 %, respectively; p = 0.052), and failure-to-rescue (11.6 and 6.1 %, respectively; p = 0.078). In multivariate analysis, PCI > 7 (95 % CI 1.051-5.798, p = 0.038) and HIPEC duration (95 % CI 1.106-6.235, p = 0.028) were independent factors associated with morbidity in elderly patients. CONCLUSIONS: CRS and HIPEC appear feasible for selected patients older than aged 70 years, albeit with a higher risk of medical complications associated with increased mortality.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02297800
Contributeur : Anthony Herrada <>
Soumis le : jeudi 26 septembre 2019 - 14:36:12
Dernière modification le : mercredi 1 avril 2020 - 11:56:02

Identifiants

Citation

Mohammad Alyami, Peter Lundberg, Vahan Kepenekian, Diane Goere, Jean-Marc Bereder, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: A case-controlled, multicenter study. Annals of Surgical Oncology, Springer Verlag, 2016, 23 (S5), pp.737-745. ⟨10.1245/s10434-016-5519-2⟩. ⟨hal-02297800⟩

Partager

Métriques

Consultations de la notice

115